Bellus Health (NYSE:BLU) Stock Rating Upgraded by Zacks Investment Research
According to Zacks, “BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs. “
Several other analysts have also commented on BLU. Jefferies Financial Group began coverage on Bellus Health in a report on Monday, September 30th. They issued a “buy” rating and a $20.00 price objective on the stock. TheStreet raised shares of Bellus Health from a “d+” rating to a “c-” rating in a research note on Friday, January 3rd. Guggenheim initiated coverage on shares of Bellus Health in a research note on Monday, September 30th. They issued a “buy” rating and a $12.00 target price on the stock. Cowen initiated coverage on shares of Bellus Health in a research note on Monday, September 30th. They issued an “outperform” rating on the stock. Finally, JBL Advisors initiated coverage on shares of Bellus Health in a research note on Monday, September 30th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.00.
Bellus Health (NYSE:BLU) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.
Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. acquired a new stake in shares of Bellus Health during the third quarter worth $257,000. Millennium Management LLC bought a new position in Bellus Health in the third quarter valued at $424,000. Finally, Orbimed Advisors LLC bought a new position in Bellus Health in the third quarter valued at $45,129,000.
Bellus Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Recommended Story: Market Perform
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellus Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health and related companies with MarketBeat.com's FREE daily email newsletter.